Biology Reference
In-Depth Information
inhibition and cytotoxicity by novel poly(adenosine diphos-
phoribose) polymerase inhibitors in a panel of human tumor cell
lines.
Clin Cancer Res
2000;6(7):2860
mammary tumor cell growth by AZD2281 and cisplatin.
Clin
Cancer Res
2008;14(12):3916
25.
114. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E,
Nygren AO, Zander SA, et al. High sensitivity of BRCA1-defi-
cient mammary tumors to the PARP inhibitor AZD2281 alone
and in combination with platinum drugs.
Proc Natl Acad Sci USA
2008;105(44):17079
e
7.
97. Yung TM, Sato S, Satoh MS. Poly(ADP-ribosyl)ation as a DNA
damage-induced post-translational modification regulating pol-
y(ADP-ribose) polymerase-1-topoisomerase I interaction.
J Biol
Chem
2004;279(38):39686
e
84.
115. Liu H, Knabb JR, Spike BT, Macleod KF. Elevated poly-(ADP-
ribose)-polymerase activity sensitizes retinoblastoma-deficient
cells to DNA damage-induced necrosis.
Mol Cancer Res
2009;7(7):1099
96.
98. Malanga M, Althaus FR. Poly(ADP-ribose) reactivates stalled
DNA topoisomerase I and induces DNA strand break resealing.
J Biol Chem
2004;279(7):5244
e
e
8.
99. Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly
(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to
topoisomerase I poisons by increasing the persistence of DNA
strand breaks.
Clin Cancer Res
2005;11(23):8449
e
109.
116. Racz I, Tory K, Gallyas Jr F, Berente Z, Osz E, Jaszlits L, et al. BGP-
15
e
protects
against nephrotoxicity of cisplatin without compromising its
antitumor activity.
Biochem Pharmacol
2002;63(6):1099
e
a novel poly(ADP-ribose) polymerase inhibitor
e
57.
100. Caldecott K, Jeggo P. Cross-sensitivity of gamma-ray-sensitive
hamster mutants to cross-linking agents.
Mutat Res
1991;255(2):
111
e
111.
117. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z,
Kyle S, et al. Preclinical selection of a novel poly (ADP-ribose)
polymerase
e
21.
101. Barrows LR, Holden JA, Anderson M, D'Arpa P. The CHO
XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits
hypersensitivity to camptothecin independent of DNA replica-
tion.
Mutat Res
1998;408(2):103
e
inhibitor
for
clinical
trial.
Mol Cancer Ther
56.
118. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I,
McHugh P, et al. Temozolomide pharmacodynamics in patients
with metastatic melanoma: DNA damage and activity of repair
enzymes 6-alkylguanine alkyltransferase and poly(ADP-ribose)
polymerase-1.
Clin Cancer Res
2005;11(9):3402
2007;6(3):945
e
10.
102. Park SY, Lam W, Cheng YC. X-ray repair cross-complementing
gene I protein plays an important role in camptothecin resistance.
Cancer Res
2002;62(2):459
e
9.
119. Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M,
Jowle D, et al. Lomeguatrib, a potent inhibitor of O6-alkylgua-
nine-DNA-alkyltransferase: phase I safety, pharmacodynamic,
and pharmacokinetic trial and evaluation in combination with
temozolomide in patients with advanced solid tumors.
Clin
Cancer Res
2006;12(5):1577
e
65.
103. Plo I, Liao ZY, Barcelo JM, Kohlhagen G, Caldecott KW,
Weinfeld M, et al. Association of XRCC1 and tyrosyl DNA
phosphodiesterase (Tdp1) for the repair of topoisomerase
I-mediated DNA lesions.
DNA Repair (Amst)
2003;2(10):1087
e
100.
104. Weichselbaum RR, Little JB. The differential response of human
tumours to fractionated radiation may be due to a post-irradia-
tion repair process.
Br J Cancer
1982;46(4):532
e
84.
120. Ranson M, Hersey P, Thompson D, Beith J, McArthur G,
Haydon A, et al. A randomised trial of the combination of
lomeguatrib and temozolomide alone in patients with advanced
melanoma.
J Clin Oncol
2007;25(18):2540
e
7.
105. Barendsen GW, Van Bree C, Franken NA. Importance of cell
proliferative state and potentially lethal damage repair on radi-
ation effectiveness: implications for combined tumor treatments
(review).
Int J Oncol
2001;19(2):247
e
5.
121. Gajewski TF, Sosman J, Gerson SL, Liu L, Dolan E, Lin S, et al.
Phase II trial of the O6-alkylguanine DNA alkyltransferase
inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitro-
sourea in advanced melanoma.
Clin Cancer Res
2005;11(21):
7861
e
56.
106. Khan K, Araki K, Wang D, Li G, Li X, Zhang J, et al. Head and
neck cancer radiosensitization by the novel poly(ADP-ribose)
polymerase inhibitor GPI-15427.
Head Neck
2010;32(3):381
e
91.
107. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K,
Weizheng X, et al. In vitro and in vivo radiosensitization of
glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor
E7016.
Clin Cancer Res
2009;15(2):607
e
5.
122. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME,
Delaney SM, et al. Phase I trial of temozolomide plus O6-ben-
zylguanine for patients with recurrent or progressive malignant
glioma.
J Clin Oncol
2005;23(28):7178
e
12.
108. Zhu G, Chang P, Lippard SJ. Recognition of platinum-DNA
damage
e
87.
123. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, et al.
Phase II trial of carmustine plus O(6)-benzylguanine for patients
with nitrosourea-resistant recurrent or progressive malignant
glioma.
J Clin Oncol
2002;20(9):2277
e
by
poly(ADP-ribose)
polymerase-1.
Biochemistry
83.
109. Boike GM, Petru E, Sevin BU, Averette HE, Chou TC, Penalver M,
et al. Chemical enhancement of cisplatin cytotoxicity in a human
ovarian
2010;49:6177
e
83.
124. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A,
et al. Phase I Study of the poly(ADP-ribose) polymerase inhibitor,
AG014699, in combination with temozolomide in patients with
advanced solid tumors.
Clin Cancer Res
2008;14(23):7917
e
and
cervical
cancer
cell
line.
Gynecol Oncol
22.
110. Alaoui-Jamali M, Loubaba BB, Robyn S, Tapiero H, Batist G.
Effect of DNA-repair-enzyme modulators on cytotoxicity of
L-phenylalanine mustard and cis-diamminedichloroplatinum (II)
in mammary carcinoma cells resistant to alkylating drugs.
Cancer
Chemother Pharmacol
1994;34(2):153
1990;38(3):315
e
23.
125. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P,
et al. Phase I dose-escalation and pharmacokinetic study of
temozolomide (SCH 52365) for refractory or relapsing malig-
nancies.
Br J Cancer
1999;81(6):1022
e
8.
111. Bernges F, Zeller WJ. Combination effects of poly(ADP-ribose)
polymerase inhibitors and DNA-damaging agents in ovarian
tumor cell lines
e
30.
126. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W,
Seiter S, et al. Randomized phase III study of temozolomide
versus dacarbazine in the treatment of patients with advanced
metastatic malignant melanoma.
J Clin Oncol
2000;18(1):158
e
with special reference to cisplatin.
J Cancer Res
Clin Oncol
1996;122(11):665
e
70.
112. Guggenheim ER, Ondrus AE, Movassaghi M, Lippard SJ. Poly
(ADP-ribose) polymerase-1 activity facilitates the dissociation of
nuclear proteins from platinum-modified DNA.
Bioorg Med Chem
2008;16(23):10121
e
66.
127. Ryan CW, Dolan ME, Brockstein BB, McLendon R, Delaney SM,
Samuels BL, et al. A phase II trial of O6-benzylguanine and
carmustine in patients with advanced soft tissue sarcoma.
Cancer
Chemother Pharmacol
2006;58(5):634
e
8.
113. Evers B, Drost R, Schut E, de Bruin M, van der Burg E,
Derksen PW, et al. Selective inhibition of BRCA2-deficient
e
9.
128. Plummer R, Lorigan P, Evans J, Steven N, Middleton M,
Wilson R, et al. First and final report of a phase II study of the
e
